Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objectives of this study are: • To evaluate the safety and tolerability of three dose levels of LX3305 over 12 weeks in subjects with active RA who are also receiving stable doses of MTX; • To evaluate the efficacy of three dose levels of LX3305 by utilizing the American College of Rheumatology 20% response criteria (ACR20) at 12 weeks in subjects with active RA who are also receiving stable doses of MTX.
Critère d'inclusion
- Rheumatoid arthritis (RA)